DermWire | Newest Articles Newest Articles en-us Mon, 21 Aug 2017 21:39:11 GMT Mon, 21 Aug 2017 21:39:11 GMT DermWire Gut Bacteria May Play Preventive Role in MS New findings support the increasingly prominent hypothesis that gut bacteria play a role in autoimmune diseases such as multiple sclerosis (MS). Specifically, a study published in Cell Reports (Aug;20(6):1269-1277) shows that a bacteria present in the gut known as Prevotella histicola may possibly prevent MS. In the study, investigators found that Prevotella histicola can suppress experimental autoimmune encephalomyelitis (EAE) in a human leukocyte antigen (HLA) Class II transgenic mouse model. … Tue, 15 Aug 2017 04:00:00 GMT Stroke Rates Decreasing Among Men, Steady in Women Although stroke incidence rates are dropping overall, new findings suggest that those decreases are only seen in men. In a new study published in Neurology (published online August 9), investigators tracked all incident strokes among a population of 1.3 million at four specific periods in time: 1993-1994, 1999, 2005, and 2010. They found that rates of stroke incidence decreased over time in men but not in women. Additionally, rates were similar between women and men by 2010. The authors suggeste… Thu, 10 Aug 2017 04:00:00 GMT Recently Approved ALS Treatment Radicava Now Available Radicava (edaravone, Mitsubishi Tanabe Pharma America), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), is now available for treatment in the United States. The first FDA-approved ALS treatment option in more than 20 years, Radicava has been shown to slow the decline in the loss of physical function in ALS patients by 33 percent. Administered in 28-day cycles through an IV, patients can undergo treatment at an ALS center, physician&rsqu… Tue, 8 Aug 2017 04:00:00 GMT Non-Invasive Neuromodulation Device for Chronic Intractable Pain Cleared by FDA The FDA has cleared the Stimpod NMS460 (Xavant Technology), a non-invasive neuromodulation device for the symptomatic relief and management of chronic intractable pain. When applied to the affected area transcutaneously, the device’s proprietary hybrid pulsed radio frequency (PRF) waveform creates electromagnetic effects similar to invasive pulsed radio frequency treatments. It also incorporates nerve-locating technology, featuring a nerve-mapping probe that enables practitioners to locate… Tue, 1 Aug 2017 04:00:00 GMT Largest CTE Study in Football Players to Date Finds Pathological Diagnosis in 110 out of 111 NFL Players The already compelling evidence tying football to chronic traumatic encephalopathy (CTE) is now even stronger, with the publication of findings from the largest study yet to evaluate the brains of deceased football players. In a continuation of a study from several years ago, investigators neuropathologically diagnosed CTE in 177 of 202 brains of deceased football players. The study evaluated football players at various levels of play. A diagnosis of CTE was made in zero out of two pre-high s… Tue, 25 Jul 2017 04:00:00 GMT FDA Clears First MRI System for Neonatal Brain Imaging The FDA cleared the Embrace Neonatal MRI System, the first of its of its king specifically for neonatal brain and head imaging in neonatal intensive care units (NICU). The Embrace Neonatal MRI System may be used on neonates with a head circumference up to 38 centimeters and weight between 1 and 4.5 kilograms. The system has a temperature-controlled incubator placed directly into the MRI system, minimizing movement of the baby. If urgent access to the baby is necessary during the imaging process,… Fri, 21 Jul 2017 04:00:00 GMT CSL Behring: FDA Accepts sBLA for Hizentra® for Chronic Inflammatory Demyelinating Polyneuropathy The FDA has accepted for review CSL Behring’s supplemental Biologics License Application (BLA) for Hizentra®([Immune globulin subcutaneous [Human] 20% liquid) for the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment. "We remain committed to CIDP patients and their families and the review of this application is another step towards delivering on our promise to them." … Wed, 19 Jul 2017 04:00:00 GMT AAIC 2017: Electronic Self-Administered Test Performs Similarly to Pen-and-Paper Version in Detecting MCI and Early Dementias Findings presented at the Alzheimer’s Association International Conference in London indicate that the self-administered eSAGE (BrainTest Inc.) test performs similar to its validated pen-and-paper counterpart (SAGE) in detecting mild cognitive impairment and early dementias. Led by Douglas W. Scharre, MD, Professor of Clinical Neurology and Psychiatry at The Ohio State University Wexner Medical Center, investigators randomly selected individuals aged 50 and over who had taken SAGE to parti… Mon, 17 Jul 2017 04:00:00 GMT AAIC 2017: Healthy Diets Tied to Decreased Likelihood of Cognitive Impairment In Older Individuals The benefits of a healthy diet may extend to cognitive health, according to findings presented at the Alzheimer’s Association International Conference in London. Among nearly 6,000 older adults in the Health and Retirement study, investigators found that those who consistently followed diets long known to contribute to cardiovascular health were also more likely to maintain strong cognitive function in old age. In particular, they found that the specially designed Mediterranean-DASH Interv… Mon, 17 Jul 2017 04:00:00 GMT Sage Bionetworks Launches DREAM Challenge to Identify Best Uses for Remote Sensing Devices Sage Bionetworks has launched the Parkinson’s Disease Digital Biomarker DREAM Challenge, the first in a series of open, crowd-sourced analytical projects to help researchers identify ways to use smartphones and remote sensing devices to monitor health and disease. With funding provided by the Robert Wood Johnson Foundation and the Michael J. Fox Foundation for Parkinson’s Research, the challenge will use sensors to identify aspects of Parkinson’s disease severity. The data used… Thu, 13 Jul 2017 04:00:00 GMT Visual System Changes May Represent an Early Signal of Parkinson’s Disease Changes in the intracranial visual system may be a signal of Parkinson’s disease (PD), according to new findings published in Radiology. Using MRI, researchers evaluated 21 patients with newly diagnosed PD and 20 age-matched controls to assess white matter changes. Results showed that those with PD had significant alterations in optic radiation connectivity distribution, with decreased lateral geniculate nucleus V2 density. These individuals also demonstrated a significant increase in opti… Wed, 12 Jul 2017 04:00:00 GMT Sleep Disturbances Linked to Alzheimer’s Disease Poor sleep may be a sign that otherwise healthy individuals may have an increased risk of developing Alzheimer’s disease later in life over those who do not have sleep problems, according to a study published in the July 5, 2017 edition of Neurology. Researchers recruited 101 people who were considered at risk of developing Alzheimer’s, including those with a parent with the disease or carrying the apolipoprotein E gene. The study included a survey about sleep quality and spinal flui… Thu, 6 Jul 2017 04:00:00 GMT VNS Therapy Approved in Children Ages Four Years and Older with Partial Onset Refractory Seizures The FDA has approved the VNS Therapy (LivaNova) in patients as young as four years of age with partial onset refractory seizures. Originally approved for patients ages 12 years and older, VNS Therapy is a minimally invasive treatment option designed to prevent seizures before they start. “Epilepsy can be a very trying and debilitating disease that can hold a child back from reaching his or her full potential,” said Damien McDonald, LivaNova’s Chief Executive Officer. “Chi… Fri, 30 Jun 2017 04:00:00 GMT Phase 3 Results Suggest Promise of Investigational Alzheimer’s Agent in Mild Disease New Phase 3 findings published in the Journal of the Prevention of Alzheimer’s Disease show that Alzheon’s investigational agent tramiprosate (ALZ-801) may offer cognitive and functional benefits to patients with mild disease. Researchers analyzed APOE4/4 homozygotes based on disease severity and found that patients in the mild disease at baseline subgroup showed larger efficacy signals. Moreover, the cognitive effect of tramiprosate in patients with mild disease increased significan… Tue, 27 Jun 2017 04:00:00 GMT Low-Dose Fenfluramine Granted Orphan Status for LGS The FDA has granted orphan drug designation to ZX008 (Zogenix), an investigational treatment for Lennox Gastaut Syndrome (LGS). Zogenix will initiate a Phase 3 clinical trial in LGS in second half of this year. ZX008 is a low-dose fenfluramine liquid solution that is also under investigation for Dravet syndrome, for which it has also been granted orphan drug designation. Tue, 27 Jun 2017 04:00:00 GMT Dysport Approved for Lower Limb Spasticity The FDA has expanded the indication of Dysport (abobotulinumtoxinA, Ipsen Biopharmaceuticals) to include lower limb spasticity. In a Phase 3 study, adult patients treated with Dysport following a stroke or traumatic brain injury showed improvement in muscle tone at the ankle joint at four weeks. The duration of response for the majority of patients was between 12 to 16 weeks, while some patients experienced response for as long as 20 weeks. Repeat Dysport treatment should be administered when… Thu, 22 Jun 2017 04:00:00 GMT Phase 3 Results Published for Investigational Levodopa-Induced Dyskinesia Treatment Results from the Phase 3 EASE LID clinical trial, published online in JAMA Neurology, show that the investigational ADS-5102 (amantadine, Adamas Pharmaceuticals) reduces levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). In the randomized, double-blind, placebo-controlled study, patients who received ADS-5102 experienced a significantly greater decrease in LID at 12 weeks than those who received placebo, as measured by the Unified Dyskinesia Rating Scale (UDysR… Wed, 14 Jun 2017 04:00:00 GMT AHS 2017: Amgen’s CGRP Inhibitor Reduces Migraine Days New Phase 2 data show that Amgen’s investigational investigational CGRP inhibitor erenumab is effective at preventing migraine in patients experiencing 15 or more migraine days per month. In a study presented at the recent American Headache Society Annual Meeting in Boston, patients treated with erenumab experienced a reduction in monthly migraine days by 6.6, as compared to a 3.5-day reduction in placebo. In addition, days requiring acute pain-relief medications were also significantly re… Tue, 13 Jun 2017 04:00:00 GMT American Epilepsy Society Awards Investigators for Early Career Research The American Epilepsy Society (AES) has awarded 25 early career scientists and clinicians with fellowships or grants to support their work in epilepsy research. The award recipients include pre-doctoral and post-doctoral trainees, junior investigators establishing their independent programs, and clinicians and fellows pursuing additional training for a career in research. As part of the AES’s commitment to support those starting their careers in epilepsy research, the number of fel… Mon, 12 Jun 2017 04:00:00 GMT Anti-Alpha-Synuclein Antibody Shows Early Potential as Parkinson’s DMT PRX002, an investigational monoclonal antibody, may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in Parkinson’s disease (PD), according to a study presented at the recent International Congress of Parkinson’s Disease and Movement Disorders in Vancouver. Researchers evaluated the use of PRX002 in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. The patient population consisted of 80 predominantly Caucasian males with mi… Fri, 9 Jun 2017 04:00:00 GMT AHS 2017 Meeting: Prochlorperazine More Effective than Hydromorphone for Acute Migraine A new comparative study presented at the American Headache Society Annual Meeting in Boston shows that that, in patients who visit the emergency department for acute migraine treatment, prochorperazine is more effective than the opioid drug, hydromorphone. The randomized, double-blind, comparative study was conducted in two emergency departments (EDs) in New York City. Qualifying patients visiting the ED for acute migraine treatment were assigned to receive prochlorperazine 10 mg plus diphenhydr… Thu, 8 Jun 2017 04:00:00 GMT AHS 2017 Meeting: Non-Invasive Medical Devices Show Promise for Severe Headaches Results from studies presented at the American Headache Society Annual Meeting in Boston suggest that non-invasive medical devices offer effective interventions for individuals with migraine. New findings from a randomized, placebo-controlled study showing that non-invasive caloric vestibular stimulation (nCVS) can prevent episodic migraine. The vestibular organs comprise the sensory system within the inner ear and provide balance control and spatial orientation. Patients who used the nCVS de… Thu, 8 Jun 2017 04:00:00 GMT Smartphone Sensor Data Offer Insights Into Daily Functioning in Patients with Parkinson’s Disease Smartphones are a valuable resource in gaining mobility data in patients with Parkinson’s disease, according to new research presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders (Abstract 541). Evaluating 44 PD patients in a home-based setting using smartphone-based assessments over a 24-week period, investigators categorized data into different types of human activities and compared to the study’s clinical data. In over 25,000 hours of pas… Wed, 7 Jun 2017 04:00:00 GMT Teva’s Fremanezumab Reduces Monthly Headache Days in Phase 3 Chronic Migraine Study Results from the Phase 3 HALO study suggest that fremanezumab (Teva Pharmaceuticals) reduces the number of monthly headache days in patients with chronic migraine. Fremanezumab is a fully-humanized monoclonal antibody targeting the CGRP ligand. In the study, patients treated with fremanezumab experienced statistically significant reduction in the number of monthly headache days of at least moderate severity vs. placebo (-2.5 days) during the 12-week period after first dose, for both mon… Thu, 1 Jun 2017 04:00:00 GMT Neurodegenerative Diseases Linked by Abnormal Proteins Causing Similar Damage to Brain Cells Abnormal proteins found in Alzheimer's disease, Parkinson's disease, and Huntington's disease share a similar ability to cause damage when they invade brain cells, according to recently published findings (Acta Neuropathol, May 19, 2017). Investigators monitored amyloid assemblies in α-synuclein (α-syn), tau, and huntingtin Exon1 with pathologic polyglutamine repeats and found that they had a similar ability to induce intracellular vesicle rupture. While more research is … Tue, 30 May 2017 04:00:00 GMT